References
- American Cancer Society. Cancer treatment and survivorship facts and figures 2014 —2015. Atlanta: American Cancer Society; 2014:1–45.
- Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the childhood cancer survivor study. J Natl Cancer Inst. 2008;100:1368–1379.
- Patnaik JL, Byers T, DiGuiseppi C, et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13:R64.
- Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the childhood cancer survivor study. J Clin Oncol. 2009;27:2328–2338.
- Schindler M, Spycher BD, Ammann RA, et al. Cause-specific long-term mortality in survivors of childhood cancer in Switzerland: a population based study. Int J Cancer. 2016;139:322–333.
- DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–271.
- Barac A, Murtagh G, Carver JR, et al. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol. 2015;65(25):2739–2746.
- Ewer MS, Ali MK, Mackay B, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin. J Clin Oncol. 1984;2:112–117.
- Ewer MS, Von Hoff DD, Benjamin RS. A historical perspective of anthracycline cardiotoxicity. Heart Fail Clin. 2011;7:363–372.
- Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302–314.
- Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–717.
- Shelburne N, Adhikari B, Brell J, et al. Cancer treatment–related cardiotoxicity: current state of knowledge and future research priorities. Jnci. 2014;106:dju232.
- Lambert J, Thavendiranathan P. Controversies in the definition of cardiotoxicity: do we care? [ cited 2016 Jul 7]. Available from: https://www.acc.org/latest-in-cardiology/articles/2016/07/07/14/59/controversies-in-the-definition-of-cardiotoxicity
- Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34:1102–1111.
- Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ Res. 2016;118(6):1008–1020.
- Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820–7826.
- Khouri MG, Douglas PS, Mackey JR, et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation. 2012;126:2749–2763.
- Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900–2902.
- Witteles R Type I and type II cardiomyopathy classifications are complete nonsense. [ cited 2018 May 4]. Available from: https://www.acc.org/latest-in-cardiology/articles/2018/05/04/08/41/type-i-and-type-ii-cardiomyopathy-classifications-are-complete-nonsense-pro
- Kounis NG, Koniari I, Hahalis G. Cardio-oncology, Immuno-oncology, onco-cardiology and onco-immunology. Int J Cardiol. 2016 Nov;15(223):254–257.
- Holmes Gobel B. Chemotherapy-induced hypersensitivity reactions. Oncol Nurs Forum. 2005;32(5). Available from: https://communities.ons.org/HigherLogic/System/DownloadDocumentFile.ashx?DocumentFileKey=613b53ed-e222-484f-bcf9-59e32fa008ee
- Aapro M, Bernard-Marty C, Brain EG, et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol. 2011;22:257–267.
- Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 2012;23(Suppl 7):vii155–66.
- Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2014;27:911–939.
- Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2017;35:893–911.
- Tan C, Denlinger C cardiovascular toxicity in cancer survivors: current guidelines and future directions. Am coll of cardiology. Expert Analysis; [ cited 2018 Jun 29]. Available from: https://www.acc.org/latest-in-cardiology/articles/2018/06/29/12/57/cv-toxicity-in-cancer-survivors
- Moser EC, Meunier F. Cancer survivorship: a positive side-effect of more successful cancer treatment. Eur J Cancer Suppl. 2014;12(1):1–4.
- Loonen JJ, Blijlevens NM, Prins J, et al. Cancer survivorship care: person centered care in a multidisciplinary shared care model. Int J Integr Care. 2018;18(1):4.